This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bastani P, Kiadaliri AA. Cost-utility analysis of adjuvant therapies for breast cancer in Iran. International Journal of Technology Assessment in Health Care 2012; 28(2): 110-114

Subject indexing assigned by NLM

Adult; Aged; Aged, 80 and over; Antineoplastic Agents /economics /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /administration & Breast Neoplasms /drug therapy /economics /radiotherapy; Chemotherapy, Adjuvant /economics /statistics & Cost-Benefit Analysis /economics /statistics & Double-Blind Method; Female; Humans; Iran; Middle Aged; Psychometrics; Quality-Adjusted Life Years; Statistics as Topic; Statistics, Nonparametric; Surveys and Questionnaires; Survival Analysis; Taxoids /administration & dosage /economics; dosage /economics; numerical data; numerical data

22012020631

25/07/2012